Aug 24, 2023 · HER2-overexpressed cell lines (MC38 HER2, CT26 HER2) were generated using lentivirus transfection and HER2 was successfully overexpressed and located on the cell membrane, compared to MC38...

Jan 2, 2024 · HER2-transduced MC38 mouse colon cancer cells (MC38-HER2), CD19-expressing PANC1 epithelioid cells (PANC1-CD19) and CD19-expressing NIH/3T3 cells (NIH/3T3-CD19) were generated according...

In this study, the mouse HER2 gene was replaced with the human HER2 coding sequence in B-hHER2 CT26.WT cells and B-hHER2 MC38 cells. Several HER2-targeting antibody drugs and antibody-drug conjugates (ADCs), including trastuzumab, pertuzumab, T-DM1, DS8201, and RC48, have been approved worldwide for patients with HER2-positive tumors.

HER2 expression in tumors after in vivo growth of MC38-hHER2-Luc in wild type C57BL/6 mice. Cre-ERT2在无Tamoxifen诱导的情况下，在细胞质内处于无活性状态；当Tamoxifen诱导后，Tamoxifen的代谢产物4-OHT（雌激素类似物）与ERT结合，可使Cre-ERT2进核发挥Cre重组酶活性。 常见的基因工程小鼠可以分为两种命名方式，包括基因定点修饰的小鼠命名，比如：敲除、敲入、点突变等等，和随机转基因的小鼠命名。

May 14, 2021 · In this study we developed a bispecific antibody (BsAb) simultaneously targeting both PD1 and HER2 in an attempt to combine HER2-targeted therapy with immune checkpoint blockade for treating...

E–F Representative flow cytometry analysis of HER2 expression in sorted cells of the murine tumor cell lines MC38 (E) and B16F10 (F) after stable transduction with the truncated HER2...

Best result mouse MC38 cell line (KC-1363) for stable MC38 clone expressing exogenous human ERBB2. Learn more!

B-hHER2 MC38 plus and B-hHER2 CT26.WT cell lines demonstrate overexpression of the human HER2 protein. B-hHER2 MC38 plus and B-hHER2 CT26.WT cell lines exhibit normal tumor growth in B-hHER2 and BALB/c mice, respectively.

B-hHER2 MC38 cells were subcutaneously transplanted into B-hCD3E mice (n=5), and on 35 days post inoculation, tumor cells were harvested and assessed for human HER2 expression by flow cytometry. As shown, human HER2 was highly expressed on the surface of tumor cells.

Dec 10, 2021 · Here, we adopted a prodrug system that uses 5-fluorocytosine (5-FC) and a HER2-targeting scaffold protein, Z HER2:2891, fused with yeast cytosine deaminase (Fcy) to target HER2-overexpressing cancer cells and to convert 5-FC to a significantly more toxic chemotherapeutic, 5-fluorouracil (5-FU).